胆固醇系统在阿尔茨海默病中的参与
1Department of Pharmacology & Therapeutics, Faculty of Medicine, McGill University, Montreal, QC, Canada; Department of Pharmacology, Oxford University, Oxford, United Kingdom.
Handbook of clinical neurology
|May 8, 2025
概括
胆固醇系统对记忆至关重要. 这个系统的缺陷有助于老龄化和阿尔茨海默病的记忆丧失,导致胆固醇治疗的发展.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是一门学科.
背景情况:
- 记忆机制与中枢神经系统 (CNS) 胆系统有着固有的联系.
- 胆固醇缺乏被确定为与年龄相关的记忆力下降的原因.
- 在灵长类动物中进行的药理学研究证实了这种药物的有效性.
- 胆学假说 胆学假说
- 老年人的记忆丧失.
研究的目的:
- 探索阿尔茨海默病的胆固醇假设的历史发展和科学基础.
- 审查阿尔茨海默病胆固醇疗法的发展.
- 为了比较抗胆酶治疗的疗效与较新的治疗方法.
主要方法:
- 审查历史研究,将中枢神经系统胆能系统与记忆联系起来.
- 对灵长类动物和人类死后大脑样本的药理学研究的分析.
- 对阿尔茨海默病大脑的组织学证据的检查.
- 对胆固醇药物的临床试验结果的讨论.
主要成果:
- 在阿尔茨海默病的大脑中失去胆能标记物和核基底神经元的退化.
- 抗胆酶抑制剂的开发和改进 (例如,多尼佩西尔,里瓦斯蒂格明,兰胺).
- 证明抗胆酶的有效性取决于剩余的胆突触.
结论:
- 阿尔茨海默病的胆固醇假设指导了治疗的发展.
- 抗胆酶抑制剂仍然是阿尔茨海默病的关键症状治疗方法.
- 未来的疗法可能涉及肌性/尼古丁性激动剂或抗粉样蛋白策略,有效性取决于突触完整性.
相关概念视频
Alzheimer's Disease: Overview
323
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
323
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
562
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
562
Direct-Acting Cholinergic Agonists: Pharmacokinetics
983
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
983
Role of Neurotransmitters in Memory
311
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
311
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K


